HIV / AIDS

A five-year study highlights high virologic suppression and well-tolerated treatment in black patients.

Current guidelines and primary literature for managing persons living with HIV who have persistently low levels of HIV RNA are scarce. Considering the risks associated with this phenomenon, a call for further guidance and more robust studies are needed for these patients.

Editor-in-Chief Jason Gallagher PharmD, FCCP, FIDP, FIDSA, BCPS discusses this agent as a potential tool for preexposure prophylaxis (PrEP) against HIV infection. And if it is approved, the ability to overcome access issues in low to middle income countries that have a greater need.

The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.

The late-breaking ID Week session reported on the once-weekly oral regimen being studied for use in people with HIV who are virologically suppressed.

At ID Week 2024, ViiV Healthcare reports its long-acting PrEP, cabotegravir (Apretude), is more than 99% effective.

In the third installment of our series on injectables, long-acting injectables offer new treatment and prevention options for HIV, especially benefiting patients who struggle with daily oral medications.

Gilead’s HIV-1 capsid inhibitor, which is a twice-yearly injection, was more effective than a daily Truvada pill in a phase 3 trial.

Our panel discusses this patient group and the challenges associated with their care.

In this episode, clinicians discuss challenges associated with these topics and offer management insights on them.

In this case study, clinicians review a challenging case.

In the current state of the mpox outbreak, individuals with advanced HIV face a higher risk of severe illness, making vaccination and targeted public health measures essential.

Multimonth dispensing recipients show a notable decrease in discontinuation rates, highlighting its potential to improve long-term treatment adherence and retention in HIV care programs.

The antiviral began its development as a multidrug-resistant therapy for people with HIV, and has since been studied as PrEP intervention, with many now calling for it to be made widely available for mass distribution.

The largest head-to-head randomized clinical trial confirms results and also shows the 2-therapy regimen led to less weight gain.

Jared Baeten, MD, PhD emphasizes the importance of the innovative PURPOSE 1 study in the fight against HIV, coinciding with National HIV Testing Day, today serves as a reminder of the ongoing efforts to expand testing access and develop new tools to combat HIV globally.

Experts on HIV offer insights into switching therapies for patients with a history of resistance, highlighting ways to simplify and optimize treatment.

Zero HIV infections from the Phase 3 PURPOSE 1 Trial underscore the importance of innovative HIV prevention strategies across diverse populations.

Focusing on the importance of rapid treatment initiation in HIV, Shauna Applin, ARNP, reviews available therapies and provides clinical insights on treatment considerations.

Shauna Applin, ARNP, provides an overview of the therapeutic algorithm for patients with HIV, highlighting treatment guidelines and currently available therapies.

A panel of experts on HIV discuss decision-making practices for patients who have suboptimal response to their current treatment regimen.

Focusing on the management of patients with HIV, the panel provides clinical insights on treatment selection, focusing on long-acting agents.

The panel discusses strategies to predict patients who will have poor adherence to their HIV medications and how to select the best treatment options for them.

Experts on HIV provide clinical insights on testing for drug resistance prior to treatment and approaching the topic of resistance with patients.

Paul E. Sax, MD, and Sorana Segal-Maurer, MD, discuss treatment resistance in HIV and how it has changed over the years.

The panel discusses the importance of starting HIV treatment early after diagnosis and offers advice to clinical providers.

Experts on the treatment of HIV discuss how they talk with their patients about adverse effects associated with HIV regimens.

The panel offers expert perspectives on key factors that inform treatment decisions for patients with HIV.

This report underscores the increase of STIs alongside the ongoing global epidemics of HIV and viral hepatitis in the Americas and African regions.

Efforts among organizations aim to develop innovative vaccine candidates and advancements in the global fight against HIV.